Richard,
I think knowledge that PN355 boosts AZT's effectiveness is old news. I've saved most of Paracelsian's press releases. This is from their June 14, 1995 release:
"Laboratory studies suggest that Paracelsian's antiveral agent, PN355, can boost the effectiveness of AZT (zidovudine, Retrovir (R) by Glaxo Wellcome), according to a statement by John Babish, Ph.D., chief scientist at Paracelsian. Combining the therapies also enables use of lower AZT doses which may dramatically reduce toxicity problems. Extensive studies are requiered to confirm the effectiveness of the combination in humans.
"AZT has been one of the few antivirals to slow the HIV infection process, but its primary limitation is related to the high incidence of toxic side effects at therapeutic doses," said Babish. "We are encouraged by recent laboratory findings that indicate that PN355 augments inhibition of HIV when used in combination with AZT."
As far as today's press release goes, I think this is good news. Though I'm not happy about my stock being further diluted, this should prevent liquidity problems for quite a while. I am also pleased to see they are planning to come out with a product in March 1997. I am anxiously awaiting more details.
Robin Messing |
